MIT team finds that the ratio of component atoms is vital to performance.
The Whitehead Institute for Biomedical Research has been named one of 30 recipients of the prestigious CaP Cure Award for advancing research aimed at finding a cure for prostate cancer.
The principal investigator for the research award is Dr. Richard Mulligan, member of the Whitehead Institute and professor of molecular biology at MIT. Dr. Mulligan was recognized for the development of technologies that can be applied to gene therapy for advanced prostate cancer.
The $200,000 award was presented on November 5 at a dinner in Washington sponsored by Senators Robert Dole, Ted Stevens, John Glenn and Dianne Feinstein.
CaP Cure (Association for the Cure of Cancer of the Prostate) is a nonprofit organization founded by Michael R. Milkin in February 1993. Among those serving on CaP Cure boards are Dr. C. Everett Koop, Senators Dole and Feinstein, actor Edward Asner and former football star Roosevelt Grier. The 30 institutions honored at the recent dinner shared $4.3 million in grant funds.
A version of this article appeared in the November 17, 1993 issue of MIT Tech Talk (Volume 38, Number 14).